StocksMedium•5 November 2026•
1 min read
Nuvation Bio Eyes H1 2027 European Approval for IBTROZI
Key Facts
1Nuvation Bio anticipates potential European approval in the first half of next year, which could trigger a ~$30M milestone payment.
2IBTROZI net product revenue posted 18% sequential growth according to the company's latest operational update.
Nuvation Bio anticipates potential European regulatory approval for its drug IBTROZI in the first half of 2027. Seeking Alpha reported that this milestone could trigger a payment of approximately $30 million for the company. Additionally, IBTROZI net product revenue posted 18% sequential growth according to the company's latest operational update.
NUVB closed at $4.73 on November 4, 2026, with the stock trading between a low of $4.52 and a high of $4.75 during that session. This performance follows the company's efforts to expand its commercial footprint and advance its pipeline amid positive sales momentum.